HLHuiqin Li

Huiqin Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Huiqin Li has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Polyethylene Glycol Loxenatide Selectively Reduces Adiposity While Preserving Lean Body Mass in Type 2 Diabetes: A 12-Week Clinical Study

    by Rong Gu, Yunting Zhou, Xiaocen Kong, Yong Luo, Huiqin Li, Jianhua Ma

    Objective: To investigate the effects of polyethylene glycol loxenatide (PEX168) on visceral and body fat, as well as glycolipid metabolism, in patients with type 2 diabetes mellitus (T2DM). Methods: A prospective interventional study design was adopted. A total of 100 patients with type 2 diabetes mellitus (T2DM) who visited the outpatient clinic of the Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, between January and December 2023 were enrolled. On the basis of their original glucose-lowering regimen, polyethylene glycol loxenatide (PEX168) 0.2 mg was administered subcutaneously once weekly for 12 weeks. Ninety-nine patients (68 males, 31 females; mean age 53.48 ± 11.36 years) completed the 12-week treatment, while one patient was lost to follow-up. Among them, 16 patients extended treatment to one year. Glycemic parameters [glycosylated hemoglobin (HbA1c), fasting blood glucose (FBG)], continuous glucose monitoring profiles, and 25-hydroxyvitamin D (25-OH-VD) levels were assessed before and after treatment. Body composition, including visceral fat area (VFA), skeletal muscle mass, and lean body mass, was measured using bioelectrical impedance analysis. Paired t-test or Wilcoxon signed-rank test was used to compare differences before and after treatment. Results: After 12 weeks of treatment compared with baseline, improvements were observed in glycosylated hemoglobin (8.8 ± 1.11% vs 6.9 ± 0.92%, P < 0.001), fasting blood glucose (9.6 ± 2.65 mmol/L vs 7.2 ± 1.71 mmol/L, P < 0.001), body weight (75.5 ± 12.67 kg vs 74.7 ± 12.78 kg, P = 0.003), BMI (27.1 ± 3.03 kg/m2 vs 26.8 ± 3.05 kg/m2, P = 0.025), body fat mass (23.9 ± 6.12 kg vs 23.0 ± 5.86 kg, P = 0.002), VFA (120.0 ± 36.04 cm2 vs 113.7 ± 32.90 cm2, P = 0.001), and 25-OH-VD levels (48.88 [41.99, 57.88] nmol/L vs 51.60 [45.55, 64.17] nmol/L, P = 0.002). Lean body mass (LBM) remained unchanged. Conclusion: PEX168 treatment for 12 weeks not only effectively improves glycemic control, lipid profiles, and glycemic variability in patients with T2DM, but also significantly reduces visceral fat, ameliorates central obesity, and preserves skeletal muscle mass, thereby achieving “high-quality weight loss.”. Clinical Trial Registration: www.clinicaltrials.gov identifier is NCT05611684.

  • Open Access

    Intermittent Use of Flash Glucose Monitoring Improves Glycemic Control in Chinese Older Patients with Type 2 Diabetes Mellitus

    by Yonghui Hu, Rengna Yan, Yun Shen, Huiqin Li, Jianhua Ma, Xiaofei Su

    Objective: To explore the efficacy and safety of intermittent use of flash glucose monitoring (FGM) for improving glycemic control in Chinese elderly patients with type 2 diabetes mellitus (T2DM). Methods: This is a prospective observational study involving patients with T2DM aged ≥ 60 years. The study period spans 12 weeks, with participants wearing FGM at weeks 0, 5, and 10. Participants were divided into two subgroups based on HbA1c at enrollment: < 7.0% and ≥ 7.0%. The primary outcome of the study was HbA1c level. Secondary outcomes included time in range (3.9– 10mmol/L) (TIR), time below range (< 3.9mmol/L) (TBR), time above range (> 10.0mmol/L) (TAR), and glycemic variability (GV). Results: A total of 68 patients completed the 12-week FGM follow-up (age 67.9 ± 5.2 years; BMI 25.4 ± 3.3kg/m²). Overall findings revealed that compared to baseline, HbA1c decreased from 7.81 ± 1.25% to 7.44± 1.10% after 12 weeks of intermittent wearing of FGM (p < 0.001). In the subgroup analysis with HbA1c ≥ 7.0%, the results showed a significant reduction in HbA1c of 0.51mmol/L after 12 weeks (8.36 ± 0.95% vs 7.75 ± 0.97%, p < 0.001). And there was a significant reduction in TBR in the subgroup with HbA1c < 7% (p = 0.028). Multiple linear regression analysis showed that the baseline HbA1c (β = − 0.529, P< 0.001), duration of T2DM (β = 0.341, P = 0.001), and the frequency of sensor use (β = − 0.269, P = 0.043) were associated with the reduction in HbA1c level. Conclusion: Intermittent use of FGM is associated with an improvement in glycemic outcomes and reduces the risk of hypoglycemia in Chinese elderly patients with T2DM.


  • Open Access

    Effects of a Novel Glucokinase Activator, Dorzagliatin, on Glycemic Control and Glucose Fluctuation in Drug-Naïve Patients with Type 2 Diabetes Mellitus

    by Yuming Wang, Xiaofei Su, Wenli Zhang, Yunting Zhou, Xiao Zhou, Wei Yang, Huiqin Li, Jianhua Ma

    Aim. The prevalence rate of type 2 diabetes mellitus (T2DM) has been increasing and a large proportion of patients still do not achieve adequate or sustainable glycemic control on the basis of previous hypoglycemic treatment. In this present study, we explored whether dorzagliatin, a novel glucokinase activator (GKA), could improve glycemic control and lessen glucose fluctuation in drug-naïve patients with T2DM. Methods. A self-comparative observational study of 25 drug-naïve patients with T2DM (aged 1875years and HbA1c of 7.511.0) treated with dorzagliatin 75mg twice daily for 52weeks. Before and after dorzagliatin intervention, the serum levels of hemoglobin A1c (HbA1c), insulin, and C-peptide were measured repeatedly during fasting and after a mixed meal. The continuous glucose monitoring (CGM) device was also used to obtain 24-hour glucose profiles and assess the changes in glycemic variability parameters. Results. After 52weeks of treatment with dorzagliatin, a numerally greater reduction in HbA1c of 1.03 from the baseline was observed in patients with T2DM, accompanied by significant improvement in insulin resistance and insulin secretion. Moreover, the standard deviation of blood glucose (SDBG) and the mean amplitude of glycemic excursion (MAGE) derived from CGM data were significantly decreased after dorzagliatin therapy. The 24-h glucose variation profile showed that study patients had obviously lower mean glucose levels during the postprandial period from the baseline to week 52, an effect also demonstrated by the significant decrease in the incremental area under glucose concentration versus time curve for 2h (iAUC02h) after meals. Conclusions. This study suggests that dorzagliatin therapy could effectively improve glycemic control and glucose fluctuation in drug-naïve patients with T2DM.


  • Open Access

    Effect of Chiglitazar and Sitagliptin on Bone Mineral Density and Body Composition in Untreated Patients with Type 2 Diabetes

    by Yuming Wang, Yunting Zhou, Xiao Zhou, Xiaofei Su, Xiaohua Xu, Huiqin Li, Jianhua Ma

    Aim: To evaluate the changes in bone mineral density (BMD) and body composition in untreated patients with type 2 diabetes mellitus (T2DM) before and after chiglitazar or sitagliptin treatment. Methods: A total of 81 patients with T2DM were randomly divided to receive chiglitazar or sitagliptin treatment for 24 weeks (54 in the chiglitazar group and 27 in the sitagliptin group). We measured the spine lumbar BMD, hip BMD, fat mass (FM), fat-free mass (FFM), percent body fat (%BF), android FM, gynoid FM and skeleton muscle mass (SMM) using dual-energy X-ray absorptiometry (DEXA) and examined serum adiponectin (ADP) levels at baseline and the end of the study. Results: There were no significant changes in the BMD of the L2-4, femoral neck, trochanter or total hip as well as in the BMC after 24 weeks of treatment with chiglitazar or sitagliptin. After chiglitazar administration, the FM, gynoid FM and gynoid to total FM ratio were higher, while the android to total FM ratio and the android to gynoid FM ratio (AOI) were significantly lower. Sitagliptin intervention did not result in statistically significant differences in total fat loss, but it did cause significant decreases in %BF and AOI as well as increases in the FFM, gynoid to total FM ratio and SMM. The ADP levels had significantly negative associations with AOI in all eligible patients. Conclusion: The chiglitazar had no deleterious effects on BMD and resulted in body fat redistribution in untreated patients with T2DM. Trial Registration: The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT02173457).


  • Open Access

    Basal Insulin Reduces Glucose Variability and Hypoglycaemia Compared to Premixed Insulin in Type 2 Diabetes Patients: A Study Based on Continuous Glucose Monitoring Systems

    by Huiying Wang, Yunting Zhou, Yuming Wang, Tingting Cai, Yun Hu, Ting Jing, Bo Ding, Xiaofei Su, Huiqin Li, Jianhua Ma

    Aims: To examine the glycaemic variability and safety of basal and premixed insulin by using continuous glucose monitoring (CGM) systems. Methods: 393 patients with type 2 diabetes mellitus (T2DM) treated with basal or premixed insulin for more than 3 months were enrolled. Patients were classified into a basal insulin group or premixed insulin group according to their insulin regimens. CGMs were used for 72 h with their previous hypoglycaemic regimen unchanged. The following glycaemic parameters were calculated for each 24 h using CGM data. Results: Despite similar HbA1c and fasting C-peptide concentrations, glycaemic variability (GV), including the mean amplitude of glycaemic excursion (MAGE), standard deviation (SD) and coefficient of variation (CV), and the time below range (TBR) were significantly lower in the basal insulin group than these in the premixed insulin group. Night-time hypoglycaemia was lower in the basal insulin group than that in the premixed insulin group (pConclusion: Compared with basal insulin, the patients who use premixed insulin had higher GV, smaller TIR and an increased incidence of hypoglycaemia. For patients who use premixed insulin and with HbA1c < 7%, more attention needs to be given to hypoglycaemic events and asymptomatic hypoglycaemia. Clinical Trial Registration: ClinicalTrials.gov, identifier NCT03566472.


  • Open Access

    Comparative Evaluation of Chiglitazar and Sitagliptin on the Levels of Retinol-Binding Protein 4 and Its Correlation With Insulin Resistance in Patients With Type 2 Diabetes

    by Yunting Zhou, Huiying Wang, Yuming Wang, Xiaohua Xu, Fengfei Li, Junming Zhou, Ting Shan, Rong Huang, Tingting Cai, Xiaomei Liu, et al.

    Aims: We evaluated the efficacy and significant changes in the levels of retinol-binding protein 4 (RBP-4) and insulin resistance in patients with type 2 diabetes mellitus (T2DM) treated with chiglitazar versus sitagliptin. Methods: Eighty-one T2DM patients with haemoglobin A1c (HbA1c) level of 7.5%–10.0% were selected. Based on the study criteria, patients were randomly assigned to receive chiglitazar (32 mg), chiglitazar (48 mg), or sitagliptin (100 mg) orally for 24 weeks. Sociodemographic and anthropometric characteristics, lipid profiles, glucose profiles, and serum RBP-4 levels were determined at baseline and at the end of the therapy. Results: After treatment for 24 weeks, significant changes in fasting blood glucose (FBG), fasting insulin (Fins), 2 h-blood glucose (2h-BG), the score values of insulin resistance/insulin secretion/β cell function (HOMA-IR, HOMA-IS, and HOMA-β), triglyceride (TG), free fatty acid (FFA), high-density lipoprotein cholesterol (HDL-C), and RBP-4 levels were detected in patients with chiglitazar administration and sitagliptin administration. Changes in RBP-4 levels were positively correlated with changes in HOMA-IR and 2 h-BG in linear regression. Conclusions: Chiglitazar showed a greater improvement in parameters of diabetes than sitagliptin, and changes in serum RBP-4 levels were associated with changes in insulin-sensitizing parameters. Clinical Trial Registration: ClinicalTrials.gov, CT.gov identifier: NCT02173457.


  • Open Access

    Evaluating Glycemic Control During Basalin or Lantus Administration in Adults With Controlled Type 2 Diabetes Mellitus Using Continuous Glucose Monitoring

    by Huiying Wang, Yunting Zhou, Xiaofang Zhai, Bo Ding, Ting Jing, Xiaofei Su, Huiqin Li, Jianhua Ma

    Aim: This study aims at evaluating glycemic control during Basalin or Lantus administration in adults with controlled type 2 diabetes mellitus using continuous glucose monitoring system (CGM). Methods: 47 patients with well-controlled T2DM using both Basalin and oral hypoglycemic drugs were recruited. CGM were applied from day 1 to day 3 with the unchanged dose of Basalin and then removed from day 4. A washout was performed with Lantus at the same dose as Basalin from day 4 to day 10. Then patients were continued to install the CGM under Lantus administration from day 11 to day 13. Variables of CGM, such as the area under the curve (AUC) for both hyperglycemia and hypoglycemia, 24h mean blood glucose (24h MBG), 24h standard deviation of blood glucose (24h SDBG), 24h mean amplitude of glycemic excursion (24h MAGE), PT (percentage of time), and time in range (TIR), were calculated and compared between Basalin group and Lantus group. Results: The group of Lantus showed lower 24h MBG (p 13.9 mmol/L) than Basalin group. In summary, for T2DM population with HbA1c ≤ 7%, Lantus may be a better choice compared with Basalin.


  • Needle-free jet injection of insulin glargine improves glycemic control in patients with type 2 diabetes mellitus: a study based on the flash glucose monitoring system

    by Xiaocen Kong, Menghui Luo, Ling Cai, Peng Zhang, Rengna Yan, Yun Hu, Huiqin Li, Jianhua Ma

    : Needle-free jet injection of insulin has faster subcutaneous absorption than that when using an insulin pen. The aim of this study was to investigate the effects of insulin glargine injection giv...


  • Open Access

    Effects of GLP‐1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52‐Week Clinical Study

    by Ting-Ting Cai, Hui-Qin Li, Lan-Lan Jiang, Hui-Ying Wang, Meng-Hui Luo, Xiao-Fei Su, Jian-Hua Ma

    Introduction. Hypoglycemic drugs affect the bone quality and the risk of fractures in patients with type 2 diabetes mellitus (T2DM). We aimed to investigate the effects of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and insulin on bone mineral density (BMD) in T2DM. Methods. In this single‐blinded study, a total of 65 patients with T2DM were randomly assigned into four groups for 52 weeks: the exenatide group (n = 19), dulaglutide group (n = 19), insulin glargine group (n = 10), and placebo (n = 17). General clinical data were collected, and BMD was measured by dual‐energy X‐ray absorptiometry. Results. Compared with baseline, the glycosylated hemoglobin (HbA1c) decreased significantly in the exenatide (8.11 ± 0.24% vs. 7.40 ± 0.16%, P = 0.007), dulaglutide (8.77 ± 0.37% vs. 7.06 ± 0.28%, P < 0.001), and insulin glargine (8.57 ± 0.24% vs. 7.23 ± 0.25%, P < 0.001) groups after treatment. In the exenatide group, the BMD of the total hip increased. In the dulaglutide group, only the BMD of the femoral neck decreased (P = 0.027), but the magnitude of decrease was less than that in the placebo group; the BMD of L1‐L4, femoral neck, and total hip decreased significantly (P < 0.05) in the placebo group, while in the insulin glargine group, the BMD of L2, L4, and L1‐4 increased (P < 0.05). Compared with the placebo group, the BMD of the femoral neck and total hip in the exenatide group and the insulin glargine group were increased significantly (P < 0.05); compared with the exenatide group, the BMD of L4 in the insulin glargine group was also increased (P = 0.001). Conclusions. Compared with the placebo, GLP‐1RAs demonstrated an increase of BMD at multiple sites of the body after treatment, which may not exacerbate the consequences of bone fragility. Therefore, GLP‐1RAs might be considered for patients with T2DM. This trial is registered with ClinicalTrials.gov NCT01648582.


  • Open Access

    Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs

    by Menghui Luo, Xiaocen Kong, Huiying Wang, Xiaofang Zhai, Tingting Cai, Bo Ding, Yun Hu, Ting Jing, Xiaofei Su, Huiqin Li, et al.

    Aim. To evaluate the effect of an inhibitor of sodium-glucose cotransporter 2 (SGLT-2 inhibitor, dapagliflozin) on glycemic variability in type 2 diabetes mellitus (T2D) under insulin glargine combined with oral hypoglycemic drugs, using a continuous glucose monitoring system (CGMS). Methods. This prospective, self-controlled, single-center clinical trial recruited 36 patients with T2D under combined insulin glargine and oral hypoglycemic drugs. General clinical data were collected. Fasting blood glucose (FBG), postprandial blood glucose (PBG), glycosylated hemoglobin (HbA1c), and C-peptide levels were assessed before and four weeks of dapagliflozin (10 mg per day) treatment. Blood glucose was monitored for 72 hours before and after treatment using CGMS. Results. After treatment with dapagliflozin, FBG decreased from to mmol/L ( ); PBG decreased from to mmol/L ( ); HbA1c decreased from to . The proportion of patients with increased from 27.8% to 58.3%, and the proportion of patients with and without level 2 hypoglycemia increased from 27.8% to 55.6% ( ). CGMS data showed reduction of the 24 h MBG, MAGE, time-above-range (TAR, >10 mmol/L), high blood glucose index (HBGI), glucose management indicator (GMI), and incremental area under the curve of the glucose level more than 10 mmol/L ( ) and an increase of time-in-range (TIR, 3.9-10 mmol/L) with treatment. Homeostasis...